Relief Therapeutics Advances Publication of 2025 Half-Year Report
-
UK prosecutors to appeal dropped 'terrorism' case against Kneecap rapper
-
Spain, Inter Miami star Alba retiring at end of season
-
EU targets foreign steel to rescue struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarters
-
Trump talks up Canada deal chances with visiting PM
-
Knight rides her luck as England survive Bangladesh scare
-
Pro-Gaza protests flare in UK on anniversary of Hamas attack
-
Top rugby unions warn players against joining rebel R360 competition
-
Outcast Willis 'not overthinking' England absence despite Top 14 clean sweep
-
Trump says 'real chance' of Gaza peace deal
-
Macron urged to quit to end France political crisis
-
No.1 Scheffler seeks three-peat at World Challenge
-
Canadian PM visits Trump in bid to ease tariffs
-
Stocks falter, gold shines as traders weigh political turmoil
-
Senators accuse US attorney general of politicizing justice
-
LeBron's 'decision of all decisions' a PR stunt
-
Observing quantum weirdness in our world: Nobel physics explained
-
WTO hikes 2025 trade growth outlook but tariffs to bite in 2026
-
US Supreme Court hears challenge to 'conversion therapy' ban for minors
-
Italy's Gattuso expresses Gaza heartache ahead of World Cup qualifier with Israel
-
EU targets foreign steel to shield struggling sector
-
Djokovic vanquishes exhaustion to push through to Shanghai quarterfinals
-
Stocks, gold rise as investors weigh AI boom, political turmoil
-
Swiatek coasts through Wuhan debut while heat wilts players
-
Denmark's Rune calls for heat rule at Shanghai Masters
-
Japanese football official sentenced for viewing child sexual abuse images
-
Stocks, gold steady amid political upheaval
-
'Veggie burgers' face grilling in EU parliament
-
Trio wins physics Nobel for quantum mechanical tunnelling
-
Two years after Hamas attack, Israelis mourn at Nova massacre site
-
German factory orders drop in new blow to Merz
-
Man City star Stones considered retiring after injury woes
-
Kane could extend Bayern stay as interest in Premier League cools
-
Renewables overtake coal but growth slows: reports
-
OpenAI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Extreme rains hit India's premier Darjeeling tea estates
-
Raducanu retires from opening match in Wuhan heat with dizziness
-
UK's Starmer condemns pro-Palestinian protests on Oct 7 anniversary
-
Tokyo stocks hit new record as markets extend global rally
-
Japan's Takaichi eyes expanding coalition, reports say
-
Canadian PM to visit White House to talk tariffs
-
Indonesia school collapse toll hits 67 as search ends
-
Dodgers hold off Phillies, Brewers on the brink
-
Lawrence sparks Jaguars over Chiefs in NFL thriller
-
EU channels Trump with tariffs to shield steel sector
-
Labuschagne out as Renshaw returns to Australia squad for India ODIs
-
Open AI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Tokyo stocks hit new record as Asian markets extend global rally
-
Computer advances and 'invisibility cloak' vie for physics Nobel
-
Nobel literature buzz tips Swiss postmodernist, Australians for prize
NYSE - LSE
| RYCEF | -1.03% | 15.54 | $ | |
| AZN | 0.61% | 86.015 | $ | |
| RELX | -2.02% | 45.49 | $ | |
| GSK | 0.24% | 43.555 | $ | |
| CMSC | -0.21% | 23.75 | $ | |
| BTI | 1.42% | 51.915 | $ | |
| NGG | 0.47% | 74.25 | $ | |
| BP | -0.11% | 34.79 | $ | |
| RIO | -0.64% | 66.555 | $ | |
| RBGPF | 0% | 78.22 | $ | |
| VOD | -0.27% | 11.26 | $ | |
| SCS | -0.53% | 16.89 | $ | |
| JRI | -0.35% | 14.13 | $ | |
| BCC | 0.03% | 75.204 | $ | |
| BCE | 0.43% | 23.29 | $ | |
| CMSD | -0.25% | 24.38 | $ |
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.
The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
D.Cunningha--AMWN
